NRX Pharmaceuticals, Inc. NRXP Financial Statement Data


2025 Q2

Submissions

Field Row 1
adsh 0001437749-25-017252
cik 1719406
name NRX PHARMACEUTICALS, INC.
sic 2834
countryba US
stprba DE
cityba WILMINGTON
zipba 19801
bas1 1201 ORANGE STREET
bas2 SUITE 600
baph 484-254-6134
countryma US
stprma DE
cityma WILMINGTON
zipma 19801
mas1 1201 ORANGE STREET
mas2 SUITE 600
countryinc US
stprinc DE
ein 822844431
former BIG ROCK PARTNERS ACQUISITION CORP.
changed 20171012
afs 4-NON
wksi 0
fye 1231
form 10-Q
period 20250331
fy 2024
fp Q1
filed 20250515
accepted 2025-05-15 17:01:00.0
prevrpt 0
detail 1
instance nrxp20250331c_10q_htm.xml
nciks 1
aciks

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
cik Central Index Key (CIK). Ten digit number assigned by the SEC to each registrant that submits filings.
name Name of registrant. This corresponds to the name of the legal entity as recorded in EDGAR as of the filing date.
sic Standard Industrial Classification (SIC). Four digit code assigned by the SEC as of the filing date, indicating the registrant’s type of business.
countryba The ISO 3166-1 country of the registrant's business address.
stprba The state or province of the registrant’s business address, if field countryba is US or CA.
cityba The city of the registrant's business address.
zipba The zip code of the registrant’s business address.
bas1 The first line of the street of the registrant’s business address.
bas2 The second line of the street of the registrant’s business address.
baph The phone number of the registrant’s business address.
countryma The ISO 3166-1 country of the registrant's mailing address.
stprma The state or province of the registrant’s mailing address, if field countryma is US or CA.
cityma The city of the registrant's mailing address.
zipma The zip code of the registrant’s mailing address.
mas1 The first line of the street of the registrant’s mailing address.
mas2 The second line of the street of the registrant’s mailing address.
countryinc The ISO 3166-1 country of incorporation for the registrant.
stprinc The state or province of incorporation for the registrant, if countryinc is US or CA.
ein Employee Identification Number, 9 digit identification number assigned by the Internal Revenue Service to business entities operating in the United States.
former Most recent former name of the registrant, if any.
changed Date of change from the former name, if any.
afs Filer status with the SEC at the time of submission:
1-LAF=Large Accelerated, 2-ACC=Accelerated, 3-SRA=Smaller Reporting Accelerated, 4-NON=Non-Accelerated, 5-SML=Smaller Reporting Filer, NULL=not assigned.
wksi Well Known Seasoned Issuer (WKSI). An issuer that meets specific SEC requirements at some point during a 60-day period preceding the date the issuer satisfies its obligation to update its shelf registration statement.
fye Fiscal Year End Date, rounded to nearest month-end.
form The submission type of the registrant’s filing.
period Balance Sheet Date, rounded to nearest month-end.
fy Fiscal Year Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8).
fp Fiscal Period Focus (as defined in the EDGAR XBRL Guide Ch. 3.1.8) within Fiscal Year.
filed The date of the registrant’s filing with the Commission.
accepted The acceptance date and time of the registrant’s filing with the Commission.
prevrpt Previous Report – TRUE indicates that the submission information was subsequently amended.
detail TRUE indicates that the XBRL submission contains quantitative disclosures within the footnotes and schedules at the required detail level (e.g., each amount).
instance The name of the submitted XBRL Instance Document. The name often begins with the company ticker symbol.
nciks Number of Central Index Keys (CIK) of registrants (i.e., business units) included in the consolidating entity’s submitted filing.
aciks Additional CIKs of co-registrants included in a consolidating entity’s EDGAR submission, separated by spaces. If there are no other co-registrants (i.e., nciks=1), the value of aciks is NULL. For a very small number of filers, the entire list of co-registrants is too long to fit in the field. Where this is the case, users should refer to the complete submission file for all CIK information.

Numbers

adsh ddate tag value uom qtrs version segments coreg footnote
0001437749-25-017252 20250331 Adjustments To Additional Paid In Capital Amortization Of Prepaid Offering Costs 7000.0000 USD 1 0001437749-25-017252 Equity Components= Additional Paid In Capital;
0001437749-25-017252 20250331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 0.0000 USD 1 us-gaap/2025 Equity Components= Common Stock;
0001437749-25-017252 20240229 Adjustments To Additional Paid In Capital Warrant Issued 100000.0000 USD 0 us-gaap/2025 Class Of Warrant Or Right= Underwriter Overallotment Warrants;
0001437749-25-017252 20240331 Adjustments To Additional Paid In Capital Warrant Issued 0.0000 USD 1 us-gaap/2025 Equity Components= Common Stock; Subsidiary Sale Of Stock= Warrants Issued For Alvogen Agreement Amendment;
0001437749-25-017252 20240331 Adjustments To Additional Paid In Capital Warrant Issued 0.0000 USD 1 us-gaap/2025 Equity Components= Retained Earnings; Subsidiary Sale Of Stock= Warrants Issued For Alvogen Agreement Amendment;
0001437749-25-017252 20240430 Adjustments To Additional Paid In Capital Warrant Issued 100000.0000 USD 0 us-gaap/2025 Class Of Warrant Or Right= Underwriter Overallotment Warrants;
0001437749-25-017252 20250331 Amortization Of Prepaid Deferred Offering Costs 7000.0000 USD 1 0001437749-25-017252
0001437749-25-017252 20241231 Assets Current 3302000.0000 USD 0 us-gaap/2025
0001437749-25-017252 20241231 Cash And Cash Equivalents At Carrying Value 1443000.0000 USD 0 us-gaap/2025
0001437749-25-017252 20241231 Common Stock Shares Authorized 500000000.0000 shares 0 us-gaap/2025
0001437749-25-017252 20250331 Common Stock Value 17000.0000 USD 0 us-gaap/2025
0001437749-25-017252 20250331 Convertible Long Term Notes Payable 0.0000 USD 0 us-gaap/2025 Debt Instrument= Anson Convertible Notes;
0001437749-25-017252 20240331 Debt Conversion Converted Instrument Amount1 400000.0000 USD 1 us-gaap/2025 Debt Conversion By Unique Description= Conversion Of Principal And Interest Into Common Stock;
0001437749-25-017252 20240930 Debt Issuance Costs 375000.0000 USD 0 0001437749-25-017252 Debt Instrument= Anson Second Tranche Notes;
0001437749-25-017252 20250331 Debt Issuance Costs 350000.0000 USD 1 0001437749-25-017252
0001437749-25-017252 20250331 Fair Value Adjustment Of Warrants -2896000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20240331 Gain Loss On Convertible Debt Redemption 0.0000 USD 1 0001437749-25-017252
0001437749-25-017252 20241231 Gain Loss On Convertible Debt Redemption -1300000.0000 USD 4 0001437749-25-017252 Debt Conversion By Unique Description= Conversion Of Principal And Interest Into Common Stock; Debt Instrument= Anson First Tranche Notes;
0001437749-25-017252 20250331 Gain Loss On Convertible Debt Redemption -100000.0000 USD 1 0001437749-25-017252 Debt Conversion By Unique Description= Conversion Of Principal And Interest Into Common Stock; Debt Instrument= Anson Third Tranche Notes;
0001437749-25-017252 20240331 Gains Losses On Extinguishment Of Debt 0.0000 USD 1 us-gaap/2025
0001437749-25-017252 20250331 Increase Decrease In Accrued Liabilities And Other Operating Liabilities -337000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20240331 Increase Decrease In Prepaid Deferred Expense And Other Assets -250000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20250331 Interest Expense Nonoperating 0.0000 USD 1 us-gaap/2025 Consolidation Items= Operating Segments;
0001437749-25-017252 20240331 Interest Paid Net 374000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20250331 Liabilities 32751000.0000 USD 0 us-gaap/2025
0001437749-25-017252 20241231 Liabilities And Stockholders Equity 3651000.0000 USD 0 us-gaap/2025
0001437749-25-017252 20250331 Liabilities Current 32751000.0000 USD 0 us-gaap/2025
0001437749-25-017252 20240331 Litigation Settlement Expense 0.0000 USD 1 us-gaap/2025
0001437749-25-017252 20240331 Net Income Loss 0.0000 USD 1 us-gaap/2025 Equity Components= Additional Paid In Capital;
0001437749-25-017252 20250331 Net Income Loss 0.0000 USD 1 us-gaap/2025 Equity Components= Common Stock;
0001437749-25-017252 20240331 Operating Expenses 5998000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20230331 Operating Income Loss -3847000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20241231 Preferred Stock Shares Authorized 50000000.0000 shares 0 us-gaap/2025 Class Of Stock= Nondesignated Preferred Stock;
0001437749-25-017252 20250331 Preferred Stock Shares Issued 0.0000 shares 0 us-gaap/2025 Class Of Stock= Series A Convertible Preferred Stock;
0001437749-25-017252 20241231 Preferred Stock Value 0.0000 USD 0 us-gaap/2025 Class Of Stock= Nondesignated Preferred Stock;
0001437749-25-017252 20241231 Prepaid Expense And Other Assets Current 1859000.0000 USD 0 us-gaap/2025
0001437749-25-017252 20250331 Proceeds From Issuance Of Common Stock And Warrants Net 3255000.0000 USD 1 0001437749-25-017252 Class Of Warrant Or Right= Consideration Warrants;
0001437749-25-017252 20240331 Repayments Of Convertible Debt 2155000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20250331 Shares Outstanding 0.0000 shares 0 us-gaap/2025 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001437749-25-017252 20231231 Stockholders Equity -11733000.0000 USD 0 us-gaap/2025
0001437749-25-017252 20250331 Stockholders Equity -25161000.0000 USD 0 us-gaap/2025
0001437749-25-017252 20250331 Stockholders Equity 0.0000 USD 0 us-gaap/2025 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001437749-25-017252 20240331 Stock Issued During Period Shares Conversion Of Convertible Securities -3000000.0000 shares 1 us-gaap/2025 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001437749-25-017252 20240331 Stock Issued During Period Shares Conversion Of Units 0.0000 shares 1 us-gaap/2025 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001437749-25-017252 20240331 Stock Issued During Period Shares Conversion Of Units 143648.0000 shares 1 us-gaap/2025 Equity Components= Common Stock;
0001437749-25-017252 20240331 Stock Issued During Period Shares New Issues 0.0000 shares 1 us-gaap/2025 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock; Subsidiary Sale Of Stock= A T M Offering;
0001437749-25-017252 20240331 Stock Issued During Period Value Conversion Of Convertible Securities 0.0000 USD 1 us-gaap/2025 Equity Components= Common Stock;
0001437749-25-017252 20240331 Stock Issued During Period Value Conversion Of Units 399000.0000 USD 1 us-gaap/2025 Equity Components= Additional Paid In Capital;
0001437749-25-017252 20230831 Stock Issued During Period Value New Issues 1200000.0000 USD 0 us-gaap/2025 Class Of Stock= Series A Preferred Stock;
0001437749-25-017252 20240331 Stock Issued During Period Value New Issues 179000.0000 USD 1 us-gaap/2025 Subsidiary Sale Of Stock= A T M Offering;
0001437749-25-017252 20240331 Stock Issued During Period Value New Issues 1027000.0000 USD 1 us-gaap/2025 Subsidiary Sale Of Stock= Private Placement;
0001437749-25-017252 20250331 Stock Issued During Period Value New Issues 3255000.0000 USD 1 us-gaap/2025 Subsidiary Sale Of Stock= Registered Direct Offering;
0001437749-25-017252 20250430 Stock Issued During Period Value New Issues 100000.0000 USD 0 us-gaap/2025 Subsequent Event Type= Subsequent Event; Subsidiary Sale Of Stock= A T M Offering;
0001437749-25-017252 20250331 Stock Issued During Period Value Shares Issued From Repricing 629000.0000 USD 1 0001437749-25-017252 Equity Components= Additional Paid In Capital; Subsidiary Sale Of Stock= Consideration Shares;
0001437749-25-017252 20241231 Retained Earnings Accumulated Deficit -278273000.0000 USD 0 us-gaap/2025
0001437749-25-017252 20250331 Accrued Clinical Site Costs Current 351000.0000 USD 0 0001437749-25-017252
0001437749-25-017252 20241231 Additional Paid In Capital 255035000.0000 USD 0 us-gaap/2025
0001437749-25-017252 20240331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 242000.0000 USD 1 us-gaap/2025 Equity Components= Additional Paid In Capital;
0001437749-25-017252 20240229 Adjustments To Additional Paid In Capital Warrant Issued 500000.0000 USD 0 us-gaap/2025 Class Of Warrant Or Right= February Warrants;
0001437749-25-017252 20240331 Adjustments To Additional Paid In Capital Warrant Issued 0.0000 USD 1 us-gaap/2025 Equity Components= Accumulated Other Comprehensive Income; Subsidiary Sale Of Stock= Warrants Issued For Alvogen Agreement Amendment;
0001437749-25-017252 20250331 Assets 7590000.0000 USD 0 us-gaap/2025
0001437749-25-017252 20240731 Debt Issuance Costs 521000.0000 USD 0 0001437749-25-017252 Debt Instrument= Anson First Tranche Notes;
0001437749-25-017252 20241231 Derivative Liabilities Current 5639000.0000 USD 0 us-gaap/2025
0001437749-25-017252 20250331 Fair Value Adjustment Of Convertible Debt 965000.0000 USD 1 0001437749-25-017252
0001437749-25-017252 20250331 Fair Value Adjustment Of Convertible Debt 5376.0000 USD 1 0001437749-25-017252 Debt Instrument= Anson Convertible Notes;
0001437749-25-017252 20240331 Gain Loss On Consideration Shares And Warrants 0.0000 USD 1 0001437749-25-017252 Consolidation Items= Operating Segments;
0001437749-25-017252 20230331 Gain Loss On Convertible Debt Redemption -1593000.0000 USD 1 0001437749-25-017252
0001437749-25-017252 20240331 Income Taxes Paid Net 0.0000 USD 1 us-gaap/2025
0001437749-25-017252 20240331 Interest Expense Nonoperating 230000.0000 USD 1 us-gaap/2025 Consolidation Items= Operating Segments;
0001437749-25-017252 20250331 Loans Payable Current 0.0000 USD 0 us-gaap/2025
0001437749-25-017252 20240331 Net Cash Provided By Used In Financing Activities 395000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20230331 Net Income Loss -5512000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20250331 Net Income Loss -5512000.0000 USD 1 us-gaap/2025 Consolidation Items= Operating Segments;
0001437749-25-017252 20241231 Other Assets Noncurrent 349000.0000 USD 0 us-gaap/2025
0001437749-25-017252 20250331 Other Assets Noncurrent 334000.0000 USD 0 us-gaap/2025
0001437749-25-017252 20241231 Preferred Stock Shares Outstanding 0.0000 shares 0 us-gaap/2025 Class Of Stock= Series A Convertible Preferred Stock;
0001437749-25-017252 20250331 Repayments Of Convertible Debt 0.0000 USD 1 us-gaap/2025
0001437749-25-017252 20231231 Shares Outstanding 3000000.0000 shares 0 us-gaap/2025 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001437749-25-017252 20231231 Stockholders Equity 8000.0000 USD 0 us-gaap/2025 Equity Components= Common Stock;
0001437749-25-017252 20240331 Stockholders Equity 244599000.0000 USD 0 us-gaap/2025 Equity Components= Additional Paid In Capital;
0001437749-25-017252 20240331 Stock Issued As Offering Costs 84000.0000 USD 1 0001437749-25-017252
0001437749-25-017252 20250331 Stock Issued During Period Shares Conversion Of Units 1009518.0000 shares 1 us-gaap/2025 Equity Components= Common Stock;
0001437749-25-017252 20250331 Stock Issued During Period Shares New Issues 0.0000 shares 1 us-gaap/2025 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock; Subsidiary Sale Of Stock= Registered Direct Offering;
0001437749-25-017252 20240331 Stock Issued During Period Value Conversion Of Convertible Securities 0.0000 USD 1 us-gaap/2025 Equity Components= Retained Earnings;
0001437749-25-017252 20240331 Stock Issued During Period Value Conversion Of Units 0.0000 USD 1 us-gaap/2025 Equity Components= Retained Earnings;
0001437749-25-017252 20250331 Stock Issued During Period Value Conversion Of Units 1000.0000 USD 1 us-gaap/2025 Equity Components= Common Stock;
0001437749-25-017252 20250331 Stock Issued During Period Value Conversion Of Units 0.0000 USD 1 us-gaap/2025 Equity Components= Retained Earnings;
0001437749-25-017252 20250331 Stock Issued During Period Value New Issues 3254000.0000 USD 1 us-gaap/2025 Equity Components= Additional Paid In Capital; Subsidiary Sale Of Stock= Registered Direct Offering;
0001437749-25-017252 20240331 Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures 0.0000 USD 1 us-gaap/2025
0001437749-25-017252 20240331 Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures 0.0000 USD 1 us-gaap/2025 Equity Components= Additional Paid In Capital;
0001437749-25-017252 20250331 Stock Issued During Period Value Shares Issued From Repricing 629000.0000 USD 1 0001437749-25-017252 Subsidiary Sale Of Stock= Consideration Shares;
0001437749-25-017252 20250331 Warrants Issued1 0.0000 USD 1 0001437749-25-017252
0001437749-25-017252 20230331 Weighted Average Number Of Shares Outstanding Basic 16410062.0000 shares 1 us-gaap/2025
0001437749-25-017252 20240331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 0.0000 USD 1 us-gaap/2025 Equity Components= Common Stock;
0001437749-25-017252 20250331 Accounts Payable Current 4311000.0000 USD 0 us-gaap/2025
0001437749-25-017252 20250331 Accrued Liabilities And Other Current Liabilities 9840000.0000 USD 0 0001437749-25-017252
0001437749-25-017252 20250331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 0.0000 USD 1 us-gaap/2025 Equity Components= Accumulated Other Comprehensive Income;
0001437749-25-017252 20240331 Adjustments To Additional Paid In Capital Warrant Issued 0.0000 USD 1 us-gaap/2025 Equity Components= Additional Paid In Capital; Subsidiary Sale Of Stock= Warrants Issued For Alvogen Agreement Amendment;
0001437749-25-017252 20250331 Adjustments To Additional Paid In Capital Warrant Issued 0.0000 USD 1 us-gaap/2025 Equity Components= Retained Earnings;
0001437749-25-017252 20241231 Assets 3651000.0000 USD 0 us-gaap/2025
0001437749-25-017252 20250331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations 5548000.0000 USD 0 us-gaap/2025
0001437749-25-017252 20240731 Common Stock Par Or Stated Value Per Share 0.0010 USD 0 us-gaap/2025
0001437749-25-017252 20241231 Common Stock Par Or Stated Value Per Share 0.0010 USD 0 us-gaap/2025
0001437749-25-017252 20240331 Conversion Of Stock Amount Converted1 3000.0000 USD 1 us-gaap/2025 Conversion Of Stock By Unique Description= Conversion Of Series A Preferred Stock To Common Stock;
0001437749-25-017252 20250331 Convertible Notes Payable Current 8397000.0000 USD 0 us-gaap/2025
0001437749-25-017252 20250331 Depreciation 0.0000 USD 1 us-gaap/2025
0001437749-25-017252 20240331 Fair Value Adjustment Of Warrants 9000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20240331 Fair Value Adjustment Of Warrants 9000.0000 USD 1 us-gaap/2025 Consolidation Items= Operating Segments;
0001437749-25-017252 20250331 Fair Value Adjustment Of Warrants -2896000.0000 USD 1 us-gaap/2025 Consolidation Items= Operating Segments;
0001437749-25-017252 20250331 Fair Value Adjustment Of Warrants -2896000.0000 USD 1 us-gaap/2025 Fair Value By Liability Class= Warrants;
0001437749-25-017252 20250331 Gain Loss On Consideration Shares And Warrants -1277000.0000 USD 1 0001437749-25-017252 Consolidation Items= Operating Segments;
0001437749-25-017252 20250331 Gain Loss On Convertible Debt Redemption -1593000.0000 USD 1 0001437749-25-017252 Consolidation Items= Operating Segments;
0001437749-25-017252 20240331 Gain Loss On Issuance Of Common Stock 0.0000 USD 1 0001437749-25-017252 Consolidation Items= Operating Segments;
0001437749-25-017252 20250331 Gain Loss On Issuance Of Common Stock -730000.0000 USD 1 0001437749-25-017252 Consolidation Items= Operating Segments;
0001437749-25-017252 20240331 General And Administrative Expense 4250000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20240331 Increase Decrease In Accounts Payable 2091000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20240331 Increase Decrease In Accrued Liabilities And Other Operating Liabilities -54000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20240331 Investment Income Interest 27000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20240331 Investment Income Interest 27000.0000 USD 1 us-gaap/2025 Consolidation Items= Operating Segments;
0001437749-25-017252 20250331 Investment Income Interest 4000.0000 USD 1 us-gaap/2025 Consolidation Items= Operating Segments;
0001437749-25-017252 20241231 Liabilities Current 21863000.0000 USD 0 us-gaap/2025
0001437749-25-017252 20230331 Litigation Settlement Expense 100000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20240331 Net Cash Provided By Used In Investing Activities 0.0000 USD 1 us-gaap/2025
0001437749-25-017252 20240331 Net Income Loss -6528000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20250331 Net Income Loss -5512000.0000 USD 1 us-gaap/2025 Equity Components= Retained Earnings;
0001437749-25-017252 20240331 Payments To Acquire Productive Assets 0.0000 USD 1 us-gaap/2025
0001437749-25-017252 20230831 Preferred Stock Shares Authorized 12000000.0000 shares 0 us-gaap/2025 Class Of Stock= Series A Preferred Stock;
0001437749-25-017252 20250331 Preferred Stock Shares Authorized 50000000.0000 shares 0 us-gaap/2025 Class Of Stock= Nondesignated Preferred Stock;
0001437749-25-017252 20250331 Preferred Stock Shares Outstanding 0.0000 shares 0 us-gaap/2025 Class Of Stock= Series A Preferred Stock;
0001437749-25-017252 20240331 Share Based Compensation 242000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20240331 Shares Outstanding 0.0000 shares 0 us-gaap/2025 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001437749-25-017252 20240331 Shares Outstanding 9772672.0000 shares 0 us-gaap/2025 Equity Components= Common Stock;
0001437749-25-017252 20240331 Stockholders Equity 10000.0000 USD 0 us-gaap/2025 Equity Components= Common Stock;
0001437749-25-017252 20241231 Stockholders Equity 0.0000 USD 0 us-gaap/2025 Equity Components= Accumulated Other Comprehensive Income;
0001437749-25-017252 20250331 Stockholders Equity 258607000.0000 USD 0 us-gaap/2025 Equity Components= Additional Paid In Capital;
0001437749-25-017252 20240331 Stock Issued During Period Shares Conversion Of Convertible Securities 300000.0000 shares 1 us-gaap/2025 Equity Components= Common Stock;
0001437749-25-017252 20250331 Stock Issued During Period Shares Conversion Of Units 0.0000 shares 1 us-gaap/2025 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001437749-25-017252 20250430 Stock Issued During Period Shares New Issues 64263.0000 shares 0 us-gaap/2025 Subsequent Event Type= Subsequent Event; Subsidiary Sale Of Stock= A T M Offering;
0001437749-25-017252 20250331 Stock Issued During Period Shares Shares Issued From Repricing 0.0000 shares 1 0001437749-25-017252 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock; Subsidiary Sale Of Stock= Consideration Shares;
0001437749-25-017252 20250331 Stock Issued During Period Value Conversion Of Units 2940000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20240331 Stock Issued During Period Value New Issues USD 1 us-gaap/2025 Equity Components= Common Stock; Subsidiary Sale Of Stock= A T M Offering;
0001437749-25-017252 20240331 Stock Issued During Period Value New Issues 1344000.0000 USD 1 us-gaap/2025 Subsidiary Sale Of Stock= Common Stock And Warrant Issuance;
0001437749-25-017252 20240331 Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures 0.0000 USD 1 us-gaap/2025 Equity Components= Retained Earnings;
0001437749-25-017252 20250331 Stock Issued During Period Value Shares Issued From Repricing 0.0000 USD 1 0001437749-25-017252 Equity Components= Accumulated Other Comprehensive Income; Subsidiary Sale Of Stock= Consideration Shares;
0001437749-25-017252 20240331 Warrants Issued1 1336000.0000 USD 1 0001437749-25-017252
0001437749-25-017252 20241231 Accounts Payable Current 100000.0000 USD 0 us-gaap/2025 Related Party Transactions By Related Party= Related Party;
0001437749-25-017252 20241231 Accrued Liabilities And Other Current Liabilities 10149000.0000 USD 0 0001437749-25-017252
0001437749-25-017252 20240331 Amortization Of Prepaid Deferred Offering Costs 0.0000 USD 1 0001437749-25-017252
0001437749-25-017252 20231231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations 4595000.0000 USD 0 us-gaap/2025
0001437749-25-017252 20241231 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations 1443000.0000 USD 0 us-gaap/2025
0001437749-25-017252 20250331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect 4105000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20241231 Convertible Notes Payable Current 1246000.0000 USD 0 us-gaap/2025
0001437749-25-017252 20250331 Fair Value Adjustment Of Convertible Debt 965000.0000 USD 1 0001437749-25-017252 Consolidation Items= Operating Segments;
0001437749-25-017252 20240331 Gain Loss On Consideration Shares And Warrants 0.0000 USD 1 0001437749-25-017252
0001437749-25-017252 20250331 Gain Loss On Convertible Debt Redemption -1600000.0000 USD 1 0001437749-25-017252 Debt Conversion By Unique Description= Conversion Of Principal And Interest Into Common Stock; Debt Instrument= Anson First Tranche Notes;
0001437749-25-017252 20250331 Net Cash Provided By Used In Financing Activities 7585000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20250331 Net Income Loss 0.0000 USD 1 us-gaap/2025 Equity Components= Accumulated Other Comprehensive Income;
0001437749-25-017252 20250331 Operating Income Loss -3847000.0000 USD 1 us-gaap/2025 Consolidation Items= Operating Segments;
0001437749-25-017252 20250331 Preferred Stock Par Or Stated Value Per Share 0.0010 USD 0 us-gaap/2025
0001437749-25-017252 20250331 Preferred Stock Shares Authorized 50000000.0000 shares 0 us-gaap/2025
0001437749-25-017252 20250331 Preferred Stock Value 0.0000 USD 0 us-gaap/2025 Class Of Stock= Series A Convertible Preferred Stock;
0001437749-25-017252 20250331 Proceeds From Issuance Of Common Stock And Warrants Net 0.0000 USD 1 0001437749-25-017252 Class Of Warrant Or Right= Warrants Other Than Consideration Warrants;
0001437749-25-017252 20250331 Repayments Of Insurance Loans 320000.0000 USD 1 0001437749-25-017252
0001437749-25-017252 20240331 Research And Development Expense 1748000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20250331 Retained Earnings Accumulated Deficit -283785000.0000 USD 0 us-gaap/2025
0001437749-25-017252 20231231 Shares Outstanding 8391940.0000 shares 0 us-gaap/2025 Equity Components= Common Stock;
0001437749-25-017252 20241231 Shares Outstanding 0.0000 shares 0 us-gaap/2025 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001437749-25-017252 20231231 Stockholders Equity -3000.0000 USD 0 us-gaap/2025 Equity Components= Accumulated Other Comprehensive Income;
0001437749-25-017252 20240331 Stockholders Equity -15069000.0000 USD 0 us-gaap/2025
0001437749-25-017252 20240331 Stock Issued During Period Shares New Issues 575000.0000 shares 1 us-gaap/2025 Equity Components= Common Stock; Subsidiary Sale Of Stock= Common Stock And Warrant Issuance;
0001437749-25-017252 20240531 Stock Issued During Period Shares New Issues 91050.0000 shares 0 us-gaap/2025 Subsidiary Sale Of Stock= April Overallotment Agreement;
0001437749-25-017252 20240331 Stock Issued During Period Value Conversion Of Convertible Securities 0.0000 USD 1 us-gaap/2025 Equity Components= Accumulated Other Comprehensive Income;
0001437749-25-017252 20240331 Stock Issued During Period Value Conversion Of Units 0.0000 USD 1 us-gaap/2025 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001437749-25-017252 20250331 Stock Issued During Period Value Conversion Of Units 0.0000 USD 1 us-gaap/2025 Equity Components= Accumulated Other Comprehensive Income;
0001437749-25-017252 20250331 Stock Issued During Period Value Conversion Of Units 2939000.0000 USD 1 us-gaap/2025 Equity Components= Additional Paid In Capital;
0001437749-25-017252 20240331 Stock Issued During Period Value New Issues 0.0000 USD 1 us-gaap/2025 Equity Components= Accumulated Other Comprehensive Income; Subsidiary Sale Of Stock= A T M Offering;
0001437749-25-017252 20240331 Stock Issued During Period Value New Issues 1000.0000 USD 1 us-gaap/2025 Equity Components= Common Stock; Subsidiary Sale Of Stock= Common Stock And Warrant Issuance;
0001437749-25-017252 20240331 Stock Issued During Period Value New Issues 0.0000 USD 1 us-gaap/2025 Equity Components= Retained Earnings; Subsidiary Sale Of Stock= Private Placement;
0001437749-25-017252 20250331 Stock Issued During Period Value New Issues 0.0000 USD 1 us-gaap/2025 Equity Components= Accumulated Other Comprehensive Income; Subsidiary Sale Of Stock= Registered Direct Offering;
0001437749-25-017252 20240331 Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures 0.0000 USD 1 us-gaap/2025 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001437749-25-017252 20240331 Weighted Average Number Of Shares Outstanding Basic 8852286.0000 shares 1 us-gaap/2025
0001437749-25-017252 20250331 Adjustments To Additional Paid In Capital Amortization Of Prepaid Offering Costs 7000.0000 USD 1 0001437749-25-017252
0001437749-25-017252 20250331 Adjustments To Additional Paid In Capital Amortization Of Prepaid Offering Costs 0.0000 USD 1 0001437749-25-017252 Equity Components= Accumulated Other Comprehensive Income;
0001437749-25-017252 20250331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 12000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20250331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 12000.0000 USD 1 us-gaap/2025 Equity Components= Additional Paid In Capital;
0001437749-25-017252 20240331 Adjustments To Additional Paid In Capital Stock Issued Issuance Costs 481000.0000 USD 1 us-gaap/2025 Subsidiary Sale Of Stock= Common Stock And Warrant Issuance;
0001437749-25-017252 20240131 Adjustments To Additional Paid In Capital Warrant Issued 1300000.0000 USD 0 us-gaap/2025 Class Of Warrant Or Right= Alvogen And Lotus Warrants;
0001437749-25-017252 20250331 Adjustments To Additional Paid In Capital Warrant Issued 0.0000 USD 1 us-gaap/2025 Equity Components= Common Stock;
0001437749-25-017252 20250331 Assets Current 7256000.0000 USD 0 us-gaap/2025
0001437749-25-017252 20250331 Cash And Cash Equivalents At Carrying Value 5548000.0000 USD 0 us-gaap/2025
0001437749-25-017252 20250331 Commitments And Contingencies USD 0 us-gaap/2025
0001437749-25-017252 20241231 Common Stock Value 15000.0000 USD 0 us-gaap/2025
0001437749-25-017252 20250331 Convertible Long Term Notes Payable 0.0000 USD 0 us-gaap/2025
0001437749-25-017252 20240331 Fair Value Adjustment Of Convertible Debt 318000.0000 USD 1 0001437749-25-017252
0001437749-25-017252 20230331 Gain Loss On Consideration Shares And Warrants -1277000.0000 USD 1 0001437749-25-017252
0001437749-25-017252 20250331 Gain Loss On Consideration Shares And Warrants -1277000.0000 USD 1 0001437749-25-017252 Debt Conversion By Unique Description= Conversion Of Principal And Interest Into Common Stock; Debt Instrument= Anson Third Tranche Notes;
0001437749-25-017252 20240331 Gain Loss On Convertible Debt Redemption 0.0000 USD 1 0001437749-25-017252 Consolidation Items= Operating Segments;
0001437749-25-017252 20250131 Gain Loss On Issuance Of Common Stock 700000.0000 USD 0 0001437749-25-017252 Subsidiary Sale Of Stock= R D Purchase Agreement;
0001437749-25-017252 20250331 Income Taxes Paid Net 0.0000 USD 1 us-gaap/2025
0001437749-25-017252 20240331 Net Income Loss -6528000.0000 USD 1 us-gaap/2025 Consolidation Items= Operating Segments;
0001437749-25-017252 20241231 Preferred Stock Shares Authorized 12000000.0000 shares 0 us-gaap/2025 Class Of Stock= Series A Convertible Preferred Stock;
0001437749-25-017252 20241231 Preferred Stock Value 0.0000 USD 0 us-gaap/2025 Class Of Stock= Series A Convertible Preferred Stock;
0001437749-25-017252 20250331 Prepaid Expense And Other Assets Current 1708000.0000 USD 0 us-gaap/2025
0001437749-25-017252 20240229 Proceeds From Issuance Of Private Placement 1000000.0000 USD 0 us-gaap/2025 Subsidiary Sale Of Stock= Private Placement;
0001437749-25-017252 20240331 Proceeds From Issuance Of Private Placement 1027000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20241231 Shares Outstanding 14591505.0000 shares 0 us-gaap/2025 Equity Components= Common Stock;
0001437749-25-017252 20250331 Shares Outstanding 17120120.0000 shares 0 us-gaap/2025 Equity Components= Common Stock;
0001437749-25-017252 20241231 Stockholders Equity 255035000.0000 USD 0 us-gaap/2025 Equity Components= Additional Paid In Capital;
0001437749-25-017252 20241231 Stockholders Equity -278273000.0000 USD 0 us-gaap/2025 Equity Components= Retained Earnings;
0001437749-25-017252 20250331 Stockholders Equity 17000.0000 USD 0 us-gaap/2025 Equity Components= Common Stock;
0001437749-25-017252 20230831 Stock Issued During Period Shares New Issues 3.0000 shares 0 us-gaap/2025 Class Of Stock= Series A Preferred Stock; Subsidiary Sale Of Stock= Preferred Stock And Warrants;
0001437749-25-017252 20240229 Stock Issued During Period Shares New Issues 75000.0000 shares 0 us-gaap/2025 Subsidiary Sale Of Stock= February Overallotment Option;
0001437749-25-017252 20240331 Stock Issued During Period Shares New Issues 34584.0000 shares 1 us-gaap/2025 Equity Components= Common Stock; Subsidiary Sale Of Stock= A T M Offering;
0001437749-25-017252 20240430 Stock Issued During Period Shares New Issues 607000.0000 shares 0 us-gaap/2025 Subsidiary Sale Of Stock= April Underwriter Agreement;
0001437749-25-017252 20240331 Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures 57500.0000 shares 1 us-gaap/2025 Equity Components= Common Stock;
0001437749-25-017252 20240331 Stock Issued During Period Value Conversion Of Units 1000.0000 USD 1 us-gaap/2025 Equity Components= Common Stock;
0001437749-25-017252 20240331 Stock Issued During Period Value New Issues 0.0000 USD 1 us-gaap/2025 Equity Components= Accumulated Other Comprehensive Income; Subsidiary Sale Of Stock= Private Placement;
0001437749-25-017252 20240331 Stock Issued During Period Value New Issues 179000.0000 USD 1 us-gaap/2025 Equity Components= Additional Paid In Capital; Subsidiary Sale Of Stock= A T M Offering;
0001437749-25-017252 20240331 Stock Issued During Period Value New Issues 1027000.0000 USD 1 us-gaap/2025 Equity Components= Additional Paid In Capital; Subsidiary Sale Of Stock= Private Placement;
0001437749-25-017252 20240331 Stock Issued During Period Value New Issues 0.0000 USD 1 us-gaap/2025 Equity Components= Retained Earnings; Subsidiary Sale Of Stock= A T M Offering;
0001437749-25-017252 20250331 Stock Issued During Period Value New Issues 0.0000 USD 1 us-gaap/2025 Equity Components= Retained Earnings; Subsidiary Sale Of Stock= Registered Direct Offering;
0001437749-25-017252 20241231 Accrued Clinical Site Costs Current 379000.0000 USD 0 0001437749-25-017252
0001437749-25-017252 20250331 Adjustments To Additional Paid In Capital Amortization Of Prepaid Offering Costs 0.0000 USD 1 0001437749-25-017252 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001437749-25-017252 20240331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 242000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20240331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 0.0000 USD 1 us-gaap/2025 Equity Components= Retained Earnings;
0001437749-25-017252 20250331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 0.0000 USD 1 us-gaap/2025 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001437749-25-017252 20250331 Adjustments To Additional Paid In Capital Stock Issued Issuance Costs 245000.0000 USD 1 us-gaap/2025 Subsidiary Sale Of Stock= Registered Direct Offering;
0001437749-25-017252 20240229 Adjustments To Additional Paid In Capital Warrant Issued 100000.0000 USD 0 us-gaap/2025 Class Of Warrant Or Right= February Underwriter Warrants;
0001437749-25-017252 20240331 Adjustments To Additional Paid In Capital Warrant Issued 0.0000 USD 1 us-gaap/2025 Subsidiary Sale Of Stock= Warrants Issued For Alvogen Agreement Amendment;
0001437749-25-017252 20240331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect -3276000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20250331 Common Stock Shares Authorized 500000000.0000 shares 0 us-gaap/2025
0001437749-25-017252 20250331 Common Stock Shares Issued 17120120.0000 shares 0 us-gaap/2025
0001437749-25-017252 20250331 Common Stock Shares Outstanding 17120120.0000 shares 0 us-gaap/2025
0001437749-25-017252 20250331 Convertible Notes Payable Current 8397000.0000 USD 0 us-gaap/2025 Debt Instrument= Anson Convertible Notes;
0001437749-25-017252 20231231 Debt Conversion Converted Instrument Amount1 400000.0000 USD 0 us-gaap/2025 Debt Conversion By Unique Description= Conversion Of Debt To Common Stock; Longterm Debt Type= Convertible Debt;
0001437749-25-017252 20241231 Debt Conversion Converted Instrument Amount1 5500000.0000 USD 4 us-gaap/2025 Debt Conversion By Unique Description= Conversion Of Principal And Interest Into Common Stock; Debt Instrument= Anson Convertible Notes;
0001437749-25-017252 20250331 Debt Conversion Converted Instrument Amount1 1347000.0000 USD 1 us-gaap/2025 Debt Conversion By Unique Description= Conversion Of Principal And Interest Into Common Stock;
0001437749-25-017252 20250331 Debt Conversion Converted Instrument Amount1 2900000.0000 USD 1 us-gaap/2025 Debt Conversion By Unique Description= Conversion Of Principal And Interest Into Common Stock; Debt Instrument= Anson First Tranche Notes;
0001437749-25-017252 20240331 Depreciation 1000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20250331 Derivative Liabilities Current 9852000.0000 USD 0 us-gaap/2025
0001437749-25-017252 20230331 Earnings Per Share Basic -0.3400 USD 1 us-gaap/2025
0001437749-25-017252 20230331 Fair Value Adjustment Of Warrants -2896000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20250331 Gain Loss On Consideration Shares And Warrants -730000.0000 USD 1 0001437749-25-017252
0001437749-25-017252 20230331 General And Administrative Expense 2943000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20241231 Loans Payable Current 320000.0000 USD 0 us-gaap/2025
0001437749-25-017252 20240331 Net Income Loss 0.0000 USD 1 us-gaap/2025 Equity Components= Common Stock;
0001437749-25-017252 20250331 Net Income Loss 0.0000 USD 1 us-gaap/2025 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001437749-25-017252 20250331 Net Income Loss 0.0000 USD 1 us-gaap/2025 Equity Components= Additional Paid In Capital;
0001437749-25-017252 20230331 Nonoperating Income Expense -1665000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20240331 Nonoperating Income Expense -530000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20240331 Payments Of Debt Issuance Costs 0.0000 USD 1 us-gaap/2025
0001437749-25-017252 20250331 Payments Of Debt Issuance Costs 350000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20250331 Preferred Stock Shares Authorized 12000000.0000 shares 0 us-gaap/2025 Class Of Stock= Series A Convertible Preferred Stock;
0001437749-25-017252 20241231 Preferred Stock Shares Issued 0.0000 shares 0 us-gaap/2025 Class Of Stock= Series A Convertible Preferred Stock;
0001437749-25-017252 20240331 Proceeds From Issuance Of Common Stock And Warrants Net 0.0000 USD 1 0001437749-25-017252 Class Of Warrant Or Right= Consideration Warrants;
0001437749-25-017252 20250331 Share Based Compensation 12000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20231231 Stockholders Equity 3000.0000 USD 0 us-gaap/2025 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001437749-25-017252 20240331 Stockholders Equity 0.0000 USD 0 us-gaap/2025 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001437749-25-017252 20241231 Stockholders Equity 0.0000 USD 0 us-gaap/2025 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001437749-25-017252 20241231 Stockholders Equity 15000.0000 USD 0 us-gaap/2025 Equity Components= Common Stock;
0001437749-25-017252 20240229 Stock Issued During Period Shares New Issues 500000.0000 shares 0 us-gaap/2025 Subsidiary Sale Of Stock= February Underwriting Agreement;
0001437749-25-017252 20240229 Stock Issued During Period Shares New Issues 270000.0000 shares 0 us-gaap/2025 Subsidiary Sale Of Stock= Private Placement;
0001437749-25-017252 20240331 Stock Issued During Period Shares New Issues 270000.0000 shares 1 us-gaap/2025 Equity Components= Common Stock; Subsidiary Sale Of Stock= Private Placement;
0001437749-25-017252 20240430 Stock Issued During Period Shares New Issues 91050.0000 shares 0 us-gaap/2025 Subsidiary Sale Of Stock= April Overallotment Agreement;
0001437749-25-017252 20240731 Stock Issued During Period Shares New Issues 385515.0000 shares 2 us-gaap/2025 Subsidiary Sale Of Stock= A T M Offering;
0001437749-25-017252 20240331 Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures 0.0000 shares 1 us-gaap/2025 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001437749-25-017252 20250331 Stock Issued During Period Shares Shares Issued From Repricing 303819.0000 shares 1 0001437749-25-017252 Equity Components= Common Stock; Subsidiary Sale Of Stock= Consideration Shares;
0001437749-25-017252 20240331 Stock Issued During Period Value Conversion Of Convertible Securities 0.0000 USD 1 us-gaap/2025
0001437749-25-017252 20240331 Stock Issued During Period Value Conversion Of Convertible Securities -3000.0000 USD 1 us-gaap/2025 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001437749-25-017252 20240331 Stock Issued During Period Value Conversion Of Convertible Securities 3000.0000 USD 1 us-gaap/2025 Equity Components= Additional Paid In Capital;
0001437749-25-017252 20240331 Stock Issued During Period Value New Issues 0.0000 USD 1 us-gaap/2025 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock; Subsidiary Sale Of Stock= A T M Offering;
0001437749-25-017252 20240331 Stock Issued During Period Value New Issues 0.0000 USD 1 us-gaap/2025 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock; Subsidiary Sale Of Stock= Common Stock And Warrant Issuance;
0001437749-25-017252 20240331 Stock Issued During Period Value New Issues 1343000.0000 USD 1 us-gaap/2025 Equity Components= Additional Paid In Capital; Subsidiary Sale Of Stock= Common Stock And Warrant Issuance;
0001437749-25-017252 20240331 Stock Issued During Period Value New Issues 0.0000 USD 1 us-gaap/2025 Equity Components= Retained Earnings; Subsidiary Sale Of Stock= Common Stock And Warrant Issuance;
0001437749-25-017252 20250331 Stock Issued During Period Value New Issues 2000000.0000 USD 1 us-gaap/2025 Subsidiary Sale Of Stock= A T M Offering;
0001437749-25-017252 20240331 Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures 0.0000 USD 1 us-gaap/2025 Equity Components= Common Stock;
0001437749-25-017252 20250331 Stock Issued During Period Value Shares Issued From Repricing 0.0000 USD 1 0001437749-25-017252 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock; Subsidiary Sale Of Stock= Consideration Shares;
0001437749-25-017252 20250331 Stock Issued During Period Value Shares Issued From Repricing 0.0000 USD 1 0001437749-25-017252 Equity Components= Common Stock; Subsidiary Sale Of Stock= Consideration Shares;
0001437749-25-017252 20241231 Accounts Payable Current 4130000.0000 USD 0 us-gaap/2025
0001437749-25-017252 20250331 Additional Paid In Capital 258607000.0000 USD 0 us-gaap/2025
0001437749-25-017252 20250331 Adjustments To Additional Paid In Capital Amortization Of Prepaid Offering Costs 0.0000 USD 1 0001437749-25-017252 Equity Components= Retained Earnings;
0001437749-25-017252 20240331 Adjustments To Additional Paid In Capital Warrant Issued 0.0000 USD 1 us-gaap/2025 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock; Subsidiary Sale Of Stock= Warrants Issued For Alvogen Agreement Amendment;
0001437749-25-017252 20241231 Common Stock Shares Issued 14591505.0000 shares 0 us-gaap/2025
0001437749-25-017252 20241231 Convertible Long Term Notes Payable 5011000.0000 USD 0 us-gaap/2025
0001437749-25-017252 20250331 Debt Conversion Converted Instrument Amount1 100000.0000 USD 1 us-gaap/2025 Debt Conversion By Unique Description= Conversion Of Principal And Interest Into Common Stock; Debt Instrument= Anson Third Tranche Notes;
0001437749-25-017252 20240331 Fair Value Adjustment Of Convertible Debt 318000.0000 USD 1 0001437749-25-017252 Consolidation Items= Operating Segments;
0001437749-25-017252 20241231 Gain Loss On Convertible Debt Redemption -1300000.0000 USD 4 0001437749-25-017252 Debt Conversion By Unique Description= Conversion Of Principal And Interest Into Common Stock; Debt Instrument= Anson Convertible Notes;
0001437749-25-017252 20240331 Gain Loss On Issuance Of Common Stock 0.0000 USD 1 0001437749-25-017252
0001437749-25-017252 20250331 Gain Loss On Issuance Of Common Stock -700000.0000 USD 1 0001437749-25-017252 Subsidiary Sale Of Stock= R D Purchase Agreement;
0001437749-25-017252 20250331 Increase Decrease In Prepaid Deferred Expense And Other Assets -159000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20230331 Interest Expense Nonoperating 0.0000 USD 1 us-gaap/2025
0001437749-25-017252 20250331 Interest Paid Net 0.0000 USD 1 us-gaap/2025
0001437749-25-017252 20241231 Liabilities 26874000.0000 USD 0 us-gaap/2025
0001437749-25-017252 20240331 Net Cash Provided By Used In Operating Activities -3671000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20240331 Net Income Loss 0.0000 USD 1 us-gaap/2025 Equity Components= Accumulated Other Comprehensive Income;
0001437749-25-017252 20250331 Net Income Loss -5512000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20240331 Operating Income Loss -5998000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20241231 Preferred Stock Par Or Stated Value Per Share 0.0010 USD 0 us-gaap/2025 Class Of Stock= Nondesignated Preferred Stock;
0001437749-25-017252 20241231 Preferred Stock Par Or Stated Value Per Share 0.0010 USD 0 us-gaap/2025 Class Of Stock= Series A Convertible Preferred Stock;
0001437749-25-017252 20250331 Preferred Stock Shares Outstanding 0.0000 shares 0 us-gaap/2025 Class Of Stock= Series A Convertible Preferred Stock;
0001437749-25-017252 20250331 Preferred Stock Value 0.0000 USD 0 us-gaap/2025 Class Of Stock= Nondesignated Preferred Stock;
0001437749-25-017252 20240930 Proceeds From Convertible Debt 5000000.0000 USD 0 us-gaap/2025 Debt Instrument= Anson Second Tranche Notes;
0001437749-25-017252 20250331 Proceeds From Issuance Of Private Placement 0.0000 USD 1 us-gaap/2025
0001437749-25-017252 20240331 Repayments Of Insurance Loans 0.0000 USD 1 0001437749-25-017252
0001437749-25-017252 20230331 Research And Development Expense 804000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20231231 Stockholders Equity 241406000.0000 USD 0 us-gaap/2025 Equity Components= Additional Paid In Capital;
0001437749-25-017252 20240331 Stockholders Equity -3000.0000 USD 0 us-gaap/2025 Equity Components= Accumulated Other Comprehensive Income;
0001437749-25-017252 20250331 Stockholders Equity 0.0000 USD 0 us-gaap/2025 Equity Components= Accumulated Other Comprehensive Income;
0001437749-25-017252 20250331 Stockholders Equity -283785000.0000 USD 0 us-gaap/2025 Equity Components= Retained Earnings;
0001437749-25-017252 20250331 Stock Issued As Offering Costs 0.0000 USD 1 0001437749-25-017252
0001437749-25-017252 20240331 Stock Issued During Period Shares New Issues 0.0000 shares 1 us-gaap/2025 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock; Subsidiary Sale Of Stock= Common Stock And Warrant Issuance;
0001437749-25-017252 20240331 Stock Issued During Period Shares New Issues 0.0000 shares 1 us-gaap/2025 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock; Subsidiary Sale Of Stock= Private Placement;
0001437749-25-017252 20250131 Stock Issued During Period Shares New Issues 1215278.0000 shares 0 us-gaap/2025 Subsidiary Sale Of Stock= R D Purchase Agreement;
0001437749-25-017252 20240331 Stock Issued During Period Value Conversion Of Units 0.0000 USD 1 us-gaap/2025 Equity Components= Accumulated Other Comprehensive Income;
0001437749-25-017252 20250331 Stock Issued During Period Value Conversion Of Units 0.0000 USD 1 us-gaap/2025 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001437749-25-017252 20240331 Stock Issued During Period Value New Issues 0.0000 USD 1 us-gaap/2025 Equity Components= Common Stock; Subsidiary Sale Of Stock= Private Placement;
0001437749-25-017252 20250331 Stock Issued During Period Value New Issues 0.0000 USD 1 us-gaap/2025 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock; Subsidiary Sale Of Stock= Registered Direct Offering;
0001437749-25-017252 20250331 Stock Issued During Period Value Shares Issued From Repricing 0.0000 USD 1 0001437749-25-017252 Equity Components= Retained Earnings; Subsidiary Sale Of Stock= Consideration Shares;
0001437749-25-017252 20250331 Accounts Payable Current 200000.0000 USD 0 us-gaap/2025 Related Party Transactions By Related Party= Related Party;
0001437749-25-017252 20250331 Adjustments To Additional Paid In Capital Amortization Of Prepaid Offering Costs 0.0000 USD 1 0001437749-25-017252 Equity Components= Common Stock;
0001437749-25-017252 20240331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 0.0000 USD 1 us-gaap/2025 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001437749-25-017252 20240331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 0.0000 USD 1 us-gaap/2025 Equity Components= Accumulated Other Comprehensive Income;
0001437749-25-017252 20250331 Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value 0.0000 USD 1 us-gaap/2025 Equity Components= Retained Earnings;
0001437749-25-017252 20240331 Adjustments To Additional Paid In Capital Stock Issued Issuance Costs 48000.0000 USD 1 us-gaap/2025 Subsidiary Sale Of Stock= A T M Offering;
0001437749-25-017252 20250331 Adjustments To Additional Paid In Capital Warrant Issued 3255000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20250331 Adjustments To Additional Paid In Capital Warrant Issued 0.0000 USD 1 us-gaap/2025 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001437749-25-017252 20250331 Adjustments To Additional Paid In Capital Warrant Issued 0.0000 USD 1 us-gaap/2025 Equity Components= Accumulated Other Comprehensive Income;
0001437749-25-017252 20250331 Adjustments To Additional Paid In Capital Warrant Issued 3255000.0000 USD 1 us-gaap/2025 Equity Components= Additional Paid In Capital;
0001437749-25-017252 20240331 Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations 1319000.0000 USD 0 us-gaap/2025
0001437749-25-017252 20241231 Commitments And Contingencies USD 0 us-gaap/2025
0001437749-25-017252 20250331 Common Stock Par Or Stated Value Per Share 0.0010 USD 0 us-gaap/2025
0001437749-25-017252 20250430 Common Stock Par Or Stated Value Per Share 0.0010 USD 0 us-gaap/2025 Subsequent Event Type= Subsequent Event; Subsidiary Sale Of Stock= A T M Offering;
0001437749-25-017252 20241231 Common Stock Shares Outstanding 14591505.0000 shares 0 us-gaap/2025
0001437749-25-017252 20250331 Conversion Of Stock Amount Converted1 0.0000 USD 1 us-gaap/2025 Conversion Of Stock By Unique Description= Conversion Of Series A Preferred Stock To Common Stock;
0001437749-25-017252 20240331 Debt Issuance Costs 0.0000 USD 1 0001437749-25-017252
0001437749-25-017252 20240331 Earnings Per Share Basic -0.7400 USD 1 us-gaap/2025
0001437749-25-017252 20230331 Fair Value Adjustment Of Convertible Debt 965000.0000 USD 1 0001437749-25-017252
0001437749-25-017252 20250331 Fair Value Adjustment Of Warrants 2900000.0000 USD 1 us-gaap/2025 Class Of Warrant Or Right= Anson Warrants;
0001437749-25-017252 20250331 Gain Loss On Convertible Debt Redemption -1593000.0000 USD 1 0001437749-25-017252
0001437749-25-017252 20230331 Gain Loss On Issuance Of Common Stock -730000.0000 USD 1 0001437749-25-017252
0001437749-25-017252 20250331 Gains Losses On Extinguishment Of Debt -1277000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20250331 Increase Decrease In Accounts Payable 178000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20240331 Interest Expense Nonoperating 230000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20230331 Investment Income Interest 4000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20250331 Liabilities And Stockholders Equity 7590000.0000 USD 0 us-gaap/2025
0001437749-25-017252 20250331 Net Cash Provided By Used In Investing Activities 0.0000 USD 1 us-gaap/2025
0001437749-25-017252 20250331 Net Cash Provided By Used In Operating Activities -3480000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20240331 Net Income Loss 0.0000 USD 1 us-gaap/2025 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock;
0001437749-25-017252 20240331 Net Income Loss -6528000.0000 USD 1 us-gaap/2025 Equity Components= Retained Earnings;
0001437749-25-017252 20230331 Operating Expenses 3847000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20240331 Operating Income Loss -5998000.0000 USD 1 us-gaap/2025 Consolidation Items= Operating Segments;
0001437749-25-017252 20250331 Payments To Acquire Productive Assets 0.0000 USD 1 us-gaap/2025
0001437749-25-017252 20250331 Preferred Stock Par Or Stated Value Per Share 0.0010 USD 0 us-gaap/2025 Class Of Stock= Nondesignated Preferred Stock;
0001437749-25-017252 20250331 Preferred Stock Par Or Stated Value Per Share 0.0010 USD 0 us-gaap/2025 Class Of Stock= Series A Convertible Preferred Stock;
0001437749-25-017252 20240331 Proceeds From Convertible Debt 0.0000 USD 1 us-gaap/2025
0001437749-25-017252 20250331 Proceeds From Convertible Debt 5000000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20240331 Proceeds From Issuance Of Common Stock And Warrants Net 1523000.0000 USD 1 0001437749-25-017252 Class Of Warrant Or Right= Warrants Other Than Consideration Warrants;
0001437749-25-017252 20240331 Shares To Be Issued 270000.0000 shares 1 0001437749-25-017252 Subsidiary Sale Of Stock= Private Placement;
0001437749-25-017252 20231231 Stockholders Equity -253147000.0000 USD 0 us-gaap/2025 Equity Components= Retained Earnings;
0001437749-25-017252 20240331 Stockholders Equity -259675000.0000 USD 0 us-gaap/2025 Equity Components= Retained Earnings;
0001437749-25-017252 20241231 Stockholders Equity -23223000.0000 USD 0 us-gaap/2025
0001437749-25-017252 20250331 Stock Issued During Period Shares New Issues 1215278.0000 shares 1 us-gaap/2025 Equity Components= Common Stock; Subsidiary Sale Of Stock= Registered Direct Offering;
0001437749-25-017252 20240331 Stock Issued During Period Value Conversion Of Units 400000.0000 USD 1 us-gaap/2025
0001437749-25-017252 20240331 Stock Issued During Period Value New Issues 0.0000 USD 1 us-gaap/2025 Class Of Stock= Series A Preferred Stock; Equity Components= Preferred Stock; Subsidiary Sale Of Stock= Private Placement;
0001437749-25-017252 20240331 Stock Issued During Period Value New Issues USD 1 us-gaap/2025 Equity Components= Accumulated Other Comprehensive Income; Subsidiary Sale Of Stock= Common Stock And Warrant Issuance;
0001437749-25-017252 20250331 Stock Issued During Period Value New Issues 1000.0000 USD 1 us-gaap/2025 Equity Components= Common Stock; Subsidiary Sale Of Stock= Registered Direct Offering;
0001437749-25-017252 20240331 Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures 0.0000 USD 1 us-gaap/2025 Equity Components= Accumulated Other Comprehensive Income;

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
tag The unique identifier (name) for a tag in a specific taxonomy release.
version For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined.
ddate The end date for the data value, rounded to the nearest month end.
qtrs The count of the number of quarters represented by the data value, rounded to the nearest whole number. “0” indicates it is a point-in-time value.
uom The unit of measure for the value.
segments Tags used to represent axis and member reporting.
coreg If specified, indicates a specific co-registrant, the parent company, or other entity (e.g., guarantor). NULL indicates the consolidated entity.
value The value. This is not scaled, it is as found in the Interactive Data file, but is limited to four digits to the right of the decimal point.
footnote The text of any superscripted footnotes on the value, as shown on the statement page, truncated to 512 characters, or if there is no footnote, then this field will be blank.

Tags

tag version custom abstract datatype iord crdr tlabel doc
Fair Value Adjustment Of Convertible Debt 0001437749-25-017252 1 0 monetary D D Fair value adjustment through earnings Represents the fair value adjustment of convertible debt.
Net Cash Provided By Used In Investing Activities us-gaap/2025 0 0 monetary D D Cash Provided by (Used in) Investing Activity, Including Discontinued Operation Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.
Cash And Cash Equivalents At Carrying Value us-gaap/2025 0 0 monetary I D Cash and Cash Equivalent Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.
Common Stock Shares Authorized us-gaap/2025 0 0 shares I Common Stock, Shares Authorized The maximum number of common shares permitted to be issued by an entity's charter and bylaws.
Convertible Long Term Notes Payable us-gaap/2025 0 0 monetary I C Convertible Notes Payable, Noncurrent Carrying value as of the balance sheet date of long-term debt (with maturities initially due after one year or beyond the operating cycle if longer) identified as Convertible Notes Payable, excluding current portion. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect us-gaap/2025 0 0 monetary D D Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.
General And Administrative Expense us-gaap/2025 0 0 monetary D D General and Administrative Expense The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations us-gaap/2025 0 0 monetary I D Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Including Discontinued Operation Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.
Commitments And Contingencies us-gaap/2025 0 0 monetary I C Commitments and Contingencies Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.
Investment Income Interest us-gaap/2025 0 0 monetary D C Investment Income, Interest Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.
Litigation Settlement Expense us-gaap/2025 0 0 monetary D D Litigation Settlement, Fee Expense Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.
Amortization Of Prepaid Deferred Offering Costs 0001437749-25-017252 1 0 monetary D D Amortization of deferred offering costs to additional paid-in-capital The amortization of the prepaid deferred offering costs.
Repayments Of Insurance Loans 0001437749-25-017252 1 0 monetary D C nrxp_RepaymentsOfInsuranceLoans The repayment of insurance loans.
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value us-gaap/2025 0 0 monetary D C APIC, Share-Based Payment Arrangement, Increase for Cost Recognition Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.
Additional Paid In Capital us-gaap/2025 0 0 monetary I C Additional Paid in Capital Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.
Common Stock Shares Issued us-gaap/2025 0 0 shares I Common Stock, Shares, Issued Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.
Gains Losses On Extinguishment Of Debt us-gaap/2025 0 0 monetary D C Gain (Loss) on Extinguishment of Debt Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.
Increase Decrease In Accounts Payable us-gaap/2025 0 0 monetary D D Increase (Decrease) in Accounts Payable The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.
Shares To Be Issued 0001437749-25-017252 1 0 shares D Shares to Be Issued (in shares) Represents the number of shares to be issued during period.
Stock Issued During Period Value Shares Issued From Repricing 0001437749-25-017252 1 0 monetary D C Consideration Shares issued as a result of repricing (See Note 9) The value of shares issued from the repricing of shares.
Adjustments To Additional Paid In Capital Stock Issued Issuance Costs us-gaap/2025 0 0 monetary D D Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.
Adjustments To Additional Paid In Capital Warrant Issued us-gaap/2025 0 0 monetary D C Adjustments to Additional Paid in Capital, Warrant Issued Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.
Operating Expenses us-gaap/2025 0 0 monetary D D Operating Expenses Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.
Adjustments To Additional Paid In Capital Amortization Of Prepaid Offering Costs 0001437749-25-017252 1 0 monetary D D nrxp_AdjustmentsToAdditionalPaidInCapitalAmortizationOfPrepaidOfferingCosts Amount of decrease in additional paid in capital (APIC) resulting from the amortization of prepaid offering costs.
Operating Income Loss us-gaap/2025 0 0 monetary D C Operating Income (Loss) The net result for the period of deducting operating expenses from operating revenues.
Research And Development Expense us-gaap/2025 0 0 monetary D D Research and Development Expense Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.
Weighted Average Number Of Shares Outstanding Basic us-gaap/2025 0 0 shares D Weighted Average Number of Shares Outstanding, Basic Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
Depreciation us-gaap/2025 0 0 monetary D D Depreciation The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
Preferred Stock Par Or Stated Value Per Share us-gaap/2025 0 0 perShare I Preferred Stock, Par or Stated Value Per Share Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.
Stock Issued During Period Shares Conversion Of Convertible Securities us-gaap/2025 0 0 shares D Stock Issued During Period, Shares, Conversion of Convertible Securities Number of shares issued during the period as a result of the conversion of convertible securities.
Stock Issued During Period Value Conversion Of Units us-gaap/2025 0 0 monetary D C Stock Issued During Period, Value, Conversion of Units Value of stock issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).
Gain Loss On Convertible Debt Redemption 0001437749-25-017252 1 0 monetary D C nrxp_GainLossOnConvertibleDebtRedemption The amount of gain (loss) on convertible debt redemption.
Gain Loss On Issuance Of Common Stock 0001437749-25-017252 1 0 monetary D C nrxp_GainLossOnIssuanceOfCommonStock The amount of gain/loss on the issuance of common stock.
Proceeds From Issuance Of Common Stock And Warrants Net 0001437749-25-017252 1 0 monetary D D Proceeds from issuance of common stock and warrants, net of issuance costs The proceeds from issuance of common stock and warrants
Stock Issued During Period Shares Shares Issued From Repricing 0001437749-25-017252 1 0 shares D Consideration Shares issued as a result of repricing (See Note 9) (in shares) The number of shares issued as a result from the repricing of shares.
Fair Value Adjustment Of Warrants us-gaap/2025 0 0 monetary D D Fair Value Adjustment of Warrants Amount of expense (income) related to adjustment to fair value of warrant liability.
Earnings Per Share Basic us-gaap/2025 0 0 perShare D Earnings Per Share, Basic The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
Shares Outstanding us-gaap/2025 0 0 shares I Shares, Outstanding Number of shares issued which are neither cancelled nor held in the treasury.
Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures us-gaap/2025 0 0 shares D Stock Issued During Period, Shares, Restricted Stock Award, Net of Forfeitures Number of shares issued during the period related to Restricted Stock Awards, net of any shares forfeited.
Increase Decrease In Prepaid Deferred Expense And Other Assets us-gaap/2025 0 0 monetary D C Increase (Decrease) in Prepaid Expense and Other Assets Amount of increase (decrease) in prepaid expenses, and assets classified as other.
Preferred Stock Shares Issued us-gaap/2025 0 0 shares I Preferred Stock, Shares Issued Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.
Stock Issued During Period Shares New Issues us-gaap/2025 0 0 shares D Stock Issued During Period, Shares, New Issues Number of new stock issued during the period.
Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures us-gaap/2025 0 0 monetary D C Stock Issued During Period, Value, Restricted Stock Award, Net of Forfeitures Value of stock related to Restricted Stock Awards issued during the period, net of the stock value of such awards forfeited.
Accrued Clinical Site Costs Current 0001437749-25-017252 1 0 monetary I C Accrued clinical site costs Represents accrued clinical site costs.
Warrants Issued1 0001437749-25-017252 1 0 monetary D C Warrants issued pursuant to the Alvogen Agreement amendment Represents the cash flow effect of warrants issued during the period.
Liabilities Current us-gaap/2025 0 0 monetary I C Liabilities, Current Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.
Net Cash Provided By Used In Financing Activities us-gaap/2025 0 0 monetary D D Cash Provided by (Used in) Financing Activity, Including Discontinued Operation Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.
Common Stock Shares Outstanding us-gaap/2025 0 0 shares I Common Stock, Shares, Outstanding Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.
Nonoperating Income Expense us-gaap/2025 0 0 monetary D C Nonoperating Income (Expense) The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
Other Assets Noncurrent us-gaap/2025 0 0 monetary I D Other Assets, Noncurrent Amount of noncurrent assets classified as other.
Payments Of Debt Issuance Costs us-gaap/2025 0 0 monetary D C Payments of Debt Issuance Costs The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.
Accrued Liabilities And Other Current Liabilities 0001437749-25-017252 1 0 monetary I C Accrued and other current liabilities Amount of expenses incurred but not yet paid nor invoiced within one operating cycle, and liabilities classified as other.
Stock Issued As Offering Costs 0001437749-25-017252 1 0 monetary D C Issuance of common stock warrants as offering costs The fair value of stock issued in noncash financing activities for offering costs.
Assets us-gaap/2025 0 0 monetary I D Assets Amount of asset recognized for present right to economic benefit.
Liabilities And Stockholders Equity us-gaap/2025 0 0 monetary I C Liabilities and Equity Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.
Net Income Loss us-gaap/2025 0 0 monetary D C Net Income (Loss) Attributable to Parent The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
Stockholders Equity us-gaap/2025 0 0 monetary I C Equity, Attributable to Parent Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.
Common Stock Par Or Stated Value Per Share us-gaap/2025 0 0 perShare I Common Stock, Par or Stated Value Per Share Face amount or stated value per share of common stock.
Interest Expense Nonoperating us-gaap/2025 0 0 monetary D D Interest Expense, Nonoperating Amount of interest expense classified as nonoperating.
Loans Payable Current us-gaap/2025 0 0 monetary I C Loans Payable, Current Carrying value as of the balance sheet date of portion of long-term loans payable due within one year or the operating cycle if longer.
Prepaid Expense And Other Assets Current us-gaap/2025 0 0 monetary I D Prepaid Expense and Other Assets, Current Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.
Proceeds From Convertible Debt us-gaap/2025 0 0 monetary D D Proceeds from Convertible Debt The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
Proceeds From Issuance Of Private Placement us-gaap/2025 0 0 monetary D D Proceeds from Issuance of Private Placement The cash inflow associated with the amount received from entity's raising of capital via private rather than public placement.
Stock Issued During Period Shares Conversion Of Units us-gaap/2025 0 0 shares D Stock Issued During Period, Shares, Conversion of Units The number of shares issued during the period upon the conversion of units. An example of a convertible unit is an umbrella partnership real estate investment trust unit (UPREIT unit).
Interest Paid Net us-gaap/2025 0 0 monetary D C Interest Paid, Excluding Capitalized Interest, Operating Activity Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.
Debt Issuance Costs 0001437749-25-017252 1 0 monetary D D Expense for debt issuance costs due to fair value election on Anson Notes The cash outflow related to the issuance of debt.
Gain Loss On Consideration Shares And Warrants 0001437749-25-017252 1 0 monetary D C nrxp_GainLossOnConsiderationSharesAndWarrants The amount of gain/loss on consideration shares and warrants.
Assets Current us-gaap/2025 0 0 monetary I D Assets, Current Amount of asset recognized for present right to economic benefit, classified as current.
Liabilities us-gaap/2025 0 0 monetary I C Liabilities Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.
Increase Decrease In Accrued Liabilities And Other Operating Liabilities us-gaap/2025 0 0 monetary D D Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Amount of increase (decrease) in accrued expenses, and obligations classified as other.
Accounts Payable Current us-gaap/2025 0 0 monetary I C Accounts Payable, Current Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).
Payments To Acquire Productive Assets us-gaap/2025 0 0 monetary D C Payments to Acquire Productive Assets The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.
Preferred Stock Shares Authorized us-gaap/2025 0 0 shares I Preferred Stock, Shares Authorized The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.
Preferred Stock Shares Outstanding us-gaap/2025 0 0 shares I Preferred Stock, Shares Outstanding Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.
Share Based Compensation us-gaap/2025 0 0 monetary D D Share-Based Payment Arrangement, Noncash Expense Amount of noncash expense for share-based payment arrangement.
Debt Conversion Converted Instrument Amount1 us-gaap/2025 0 0 monetary D C Debt Conversion, Converted Instrument, Amount The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
Preferred Stock Value us-gaap/2025 0 0 monetary I C Preferred Stock, Value, Issued Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.
Repayments Of Convertible Debt us-gaap/2025 0 0 monetary D C Repayments of Convertible Debt The cash outflow from the repayment of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.
Stock Issued During Period Value Conversion Of Convertible Securities us-gaap/2025 0 0 monetary D C Stock Issued During Period, Value, Conversion of Convertible Securities The gross value of stock issued during the period upon the conversion of convertible securities.
Net Cash Provided By Used In Operating Activities us-gaap/2025 0 0 monetary D Cash Provided by (Used in) Operating Activity, Including Discontinued Operation Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.
Retained Earnings Accumulated Deficit us-gaap/2025 0 0 monetary I C Retained Earnings (Accumulated Deficit) Amount of accumulated undistributed earnings (deficit).
Common Stock Value us-gaap/2025 0 0 monetary I C Common Stock, Value, Issued Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.
Income Taxes Paid Net us-gaap/2025 0 0 monetary D C Income Taxes Paid, Net Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.
Stock Issued During Period Value New Issues us-gaap/2025 0 0 monetary D C Stock Issued During Period, Value, New Issues Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
Conversion Of Stock Amount Converted1 us-gaap/2025 0 0 monetary D D Conversion of Stock, Amount Converted The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.
Convertible Notes Payable Current us-gaap/2025 0 0 monetary I C Convertible Notes Payable, Current Carrying value as of the balance sheet date of the portion of long-term debt due within one year or the operating cycle if longer identified as Convertible Notes Payable. Convertible Notes Payable is a written promise to pay a note which can be exchanged for a specified amount of another, related security, at the option of the issuer and the holder.
Derivative Liabilities Current us-gaap/2025 0 0 monetary I C Derivative Liability, Current Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.

Description
Field Name Field Description
tag The unique identifier (name) for a tag in a specific taxonomy release.
version For a standard tag, an identifier for the taxonomy; otherwise the accession number where the tag was defined.
custom 1 if tag is custom (version=adsh), 0 if it is standard. Note: This flag is technically redundant with the version and adsh columns.
abstract 1 if the tag is not used to represent a numeric fact.
datatype If abstract=1, then NULL, otherwise the data type (e.g., monetary) for the tag.
iord If abstract=1, then NULL; otherwise, “I” if the value is a point-in time, or “D” if the value is a duration.
crdr If datatype = monetary, then the tag’s natural accounting balance (debit or credit); if not defined, then NULL.
tlabel If a standard tag, then the label text provided by the taxonomy, otherwise the text provided by the filer. A tag which had neither would have a NULL value here.
doc The detailed definition for the tag. If a standard tag, then the text provided by the taxonomy, otherwise the text assigned by the filer. Some tags have neither, and this field is NULL.

Presentation of Statements

adsh report line stmt inpth rfile tag version plabel negating
0001437749-25-017252 2 8 BS 0 H Cash And Cash Equivalents At Carrying Value us-gaap/2025 Cash and cash equivalents 0
0001437749-25-017252 2 9 BS 0 H Prepaid Expense And Other Assets Current us-gaap/2025 Prepaid expenses and other current assets 0
0001437749-25-017252 2 10 BS 0 H Assets Current us-gaap/2025 Total current assets 0
0001437749-25-017252 2 11 BS 0 H Other Assets Noncurrent us-gaap/2025 Other assets 0
0001437749-25-017252 2 12 BS 0 H Assets us-gaap/2025 Total assets 0
0001437749-25-017252 2 14 BS 0 H Accounts Payable Current us-gaap/2025 Accounts payable 0
0001437749-25-017252 2 15 BS 0 H Accrued Liabilities And Other Current Liabilities 0001437749-25-017252 Accrued and other current liabilities 0
0001437749-25-017252 2 16 BS 0 H Accrued Clinical Site Costs Current 0001437749-25-017252 Accrued clinical site costs 0
0001437749-25-017252 2 17 BS 0 H Convertible Notes Payable Current us-gaap/2025 Convertible note payable and accrued interest short term 0
0001437749-25-017252 2 18 BS 0 H Loans Payable Current us-gaap/2025 Insurance loan payable 0
0001437749-25-017252 2 19 BS 0 H Derivative Liabilities Current us-gaap/2025 Warrant liabilities 0
0001437749-25-017252 2 20 BS 0 H Liabilities Current us-gaap/2025 Total current liabilities 0
0001437749-25-017252 2 21 BS 0 H Convertible Long Term Notes Payable us-gaap/2025 Convertible note payable and accrued interest long term 0
0001437749-25-017252 2 22 BS 0 H Liabilities us-gaap/2025 Total liabilities 0
0001437749-25-017252 2 23 BS 0 H Commitments And Contingencies us-gaap/2025 Commitments and Contingencies (Note 8) 0
0001437749-25-017252 2 24 BS 0 H Preferred Stock Value us-gaap/2025 Preferred stock, $0.001 par value, 50,000,000 shares authorized; 0
0001437749-25-017252 2 25 BS 0 H Common Stock Value us-gaap/2025 Common stock, $0.001 par value, 500,000,000 shares authorized; 17,120,120 and 14,591,505 shares issued and outstanding at March 31, 2025 and December 31, 2024, respectively 0
0001437749-25-017252 2 26 BS 0 H Additional Paid In Capital us-gaap/2025 Additional paid-in capital 0
0001437749-25-017252 2 27 BS 0 H Retained Earnings Accumulated Deficit us-gaap/2025 Accumulated deficit 0
0001437749-25-017252 2 28 BS 0 H Stockholders Equity us-gaap/2025 Total stockholders deficit 0
0001437749-25-017252 2 29 BS 0 H Liabilities And Stockholders Equity us-gaap/2025 Total liabilities and stockholders' deficit 0
0001437749-25-017252 3 7 BS 1 H Preferred Stock Par Or Stated Value Per Share us-gaap/2025 Preferred stock, par value (in dollars per share) 0
0001437749-25-017252 3 8 BS 1 H Preferred Stock Shares Authorized us-gaap/2025 Preferred stock, authorized (in shares) 0
0001437749-25-017252 3 9 BS 1 H Preferred Stock Shares Issued us-gaap/2025 Preferred stock, issued (in shares) 0
0001437749-25-017252 3 10 BS 1 H Preferred Stock Shares Outstanding us-gaap/2025 Preferred stock, outstanding (in shares) 0
0001437749-25-017252 3 11 BS 1 H Common Stock Par Or Stated Value Per Share us-gaap/2025 Common stock, par value (in dollars per share) 0
0001437749-25-017252 3 12 BS 1 H Common Stock Shares Authorized us-gaap/2025 Common stock, shares authorized (in shares) 0
0001437749-25-017252 3 13 BS 1 H Common Stock Shares Issued us-gaap/2025 Common stock, shares issued (in shares) 0
0001437749-25-017252 3 14 BS 1 H Common Stock Shares Outstanding us-gaap/2025 Common stock, shares outstanding (in shares) 0
0001437749-25-017252 4 4 IS 0 H Research And Development Expense us-gaap/2025 Research and development 0
0001437749-25-017252 4 5 IS 0 H General And Administrative Expense us-gaap/2025 General and administrative 0
0001437749-25-017252 4 6 IS 0 H Litigation Settlement Expense us-gaap/2025 Settlement expense 0
0001437749-25-017252 4 7 IS 0 H Operating Expenses us-gaap/2025 Total operating expenses 0
0001437749-25-017252 4 8 IS 0 H Operating Income Loss us-gaap/2025 Loss from operations 0
0001437749-25-017252 4 10 IS 0 H Investment Income Interest us-gaap/2025 Interest income 1
0001437749-25-017252 4 11 IS 0 H Interest Expense Nonoperating us-gaap/2025 Interest expense 0
0001437749-25-017252 4 12 IS 0 H Fair Value Adjustment Of Convertible Debt 0001437749-25-017252 Fair value adjustment through earnings 0
0001437749-25-017252 4 13 IS 0 H Fair Value Adjustment Of Warrants us-gaap/2025 Change in fair value of warrant liabilities 0
0001437749-25-017252 4 14 IS 0 H Gain Loss On Issuance Of Common Stock 0001437749-25-017252 Loss on issuance of the Registered Direct Offering (see Note 9) 1
0001437749-25-017252 4 15 IS 0 H Gain Loss On Consideration Shares And Warrants 0001437749-25-017252 Loss on Consideration Shares and Warrants (see Note 9) 1
0001437749-25-017252 4 16 IS 0 H Gain Loss On Convertible Debt Redemption 0001437749-25-017252 Loss on convertible note redemptions 1
0001437749-25-017252 4 17 IS 0 H Nonoperating Income Expense us-gaap/2025 Total other expenses, net 1
0001437749-25-017252 4 18 IS 0 H Net Income Loss us-gaap/2025 Net loss 0
0001437749-25-017252 4 20 IS 0 H Earnings Per Share Basic us-gaap/2025 Basic and diluted (in dollars per share) 0
0001437749-25-017252 4 22 IS 0 H Weighted Average Number Of Shares Outstanding Basic us-gaap/2025 Basic and diluted (in shares) 0
0001437749-25-017252 5 21 EQ 0 H Shares Outstanding us-gaap/2025 Balance (in shares) 0
0001437749-25-017252 5 22 EQ 0 H Stockholders Equity us-gaap/2025 Balance 0
0001437749-25-017252 5 23 EQ 0 H Stock Issued During Period Shares Conversion Of Units us-gaap/2025 Shares issued as conversion of principal and interest for convertible note (in shares) 0
0001437749-25-017252 5 24 EQ 0 H Stock Issued During Period Value Conversion Of Units us-gaap/2025 Shares issued as conversion of principal and interest for convertible note 0
0001437749-25-017252 5 25 EQ 0 H Stock Issued During Period Shares New Issues us-gaap/2025 Stock Issued During Period, Shares, New Issues (in shares) 0
0001437749-25-017252 5 26 EQ 0 H Stock Issued During Period Value New Issues us-gaap/2025 Stock Issued During Period, Value, New Issues 0
0001437749-25-017252 5 27 EQ 0 H Adjustments To Additional Paid In Capital Warrant Issued us-gaap/2025 Fair value allocation of warrants issued with Registered Direct offering 1
0001437749-25-017252 5 28 EQ 0 H Adjustments To Additional Paid In Capital Amortization Of Prepaid Offering Costs 0001437749-25-017252 Amortization of prepaid offering costs 1
0001437749-25-017252 5 29 EQ 0 H Stock Issued During Period Shares Shares Issued From Repricing 0001437749-25-017252 Consideration Shares issued as a result of repricing (See Note 9) (in shares) 0
0001437749-25-017252 5 30 EQ 0 H Stock Issued During Period Value Shares Issued From Repricing 0001437749-25-017252 Consideration Shares issued as a result of repricing (See Note 9) 0
0001437749-25-017252 5 31 EQ 0 H Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value us-gaap/2025 Stock-based compensation 0
0001437749-25-017252 5 32 EQ 0 H Net Income Loss us-gaap/2025 Net loss 0
0001437749-25-017252 5 33 EQ 0 H Shares Outstanding us-gaap/2025 Balance (in shares) 0
0001437749-25-017252 5 34 EQ 0 H Stockholders Equity us-gaap/2025 Balance 0
0001437749-25-017252 5 35 EQ 0 H Stock Issued During Period Shares Conversion Of Convertible Securities us-gaap/2025 Conversion of Series A preferred stock into common stock (in shares) 0
0001437749-25-017252 5 36 EQ 0 H Stock Issued During Period Value Conversion Of Convertible Securities us-gaap/2025 Conversion of Series A preferred stock into common stock 0
0001437749-25-017252 5 37 EQ 0 H Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures us-gaap/2025 Vesting of restricted stock awards (in shares) 0
0001437749-25-017252 5 38 EQ 0 H Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures us-gaap/2025 Vesting of restricted stock awards 0
0001437749-25-017252 6 9 EQ 1 H Adjustments To Additional Paid In Capital Stock Issued Issuance Costs us-gaap/2025 Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs 0
0001437749-25-017252 6 10 EQ 1 H Shares To Be Issued 0001437749-25-017252 Shares to Be Issued (in shares) 0
0001437749-25-017252 7 14 CF 0 H Net Income Loss us-gaap/2025 Net loss 0
0001437749-25-017252 7 16 CF 0 H Depreciation us-gaap/2025 Depreciation expense 0
0001437749-25-017252 7 17 CF 0 H Share Based Compensation us-gaap/2025 Stock-based compensation 0
0001437749-25-017252 7 18 CF 0 H Fair Value Adjustment Of Warrants us-gaap/2025 Change in fair value of warrant liabilities 0
0001437749-25-017252 7 19 CF 0 H Fair Value Adjustment Of Convertible Debt 0001437749-25-017252 Fair value adjustment through earnings 0
0001437749-25-017252 7 20 CF 0 H Gains Losses On Extinguishment Of Debt us-gaap/2025 Loss on Consideration Shares and Warrants 1
0001437749-25-017252 7 21 CF 0 H Gain Loss On Consideration Shares And Warrants 0001437749-25-017252 Loss on issuance of Registered Direct Offering 1
0001437749-25-017252 7 22 CF 0 H Gain Loss On Convertible Debt Redemption 0001437749-25-017252 Loss on convertible note redemptions 1
0001437749-25-017252 7 23 CF 0 H Debt Issuance Costs 0001437749-25-017252 Expense for debt issuance costs due to fair value election on Anson Notes 0
0001437749-25-017252 7 25 CF 0 H Increase Decrease In Prepaid Deferred Expense And Other Assets us-gaap/2025 Prepaid expense and other assets 1
0001437749-25-017252 7 26 CF 0 H Increase Decrease In Accounts Payable us-gaap/2025 Accounts payable 0
0001437749-25-017252 7 27 CF 0 H Increase Decrease In Accrued Liabilities And Other Operating Liabilities us-gaap/2025 Accrued expense and other liabilities 0
0001437749-25-017252 7 28 CF 0 H Net Cash Provided By Used In Operating Activities us-gaap/2025 Net cash used in operating activities 0
0001437749-25-017252 7 30 CF 0 H Payments To Acquire Productive Assets us-gaap/2025 Purchase of computer equipment 1
0001437749-25-017252 7 31 CF 0 H Net Cash Provided By Used In Investing Activities us-gaap/2025 Net cash used in investing activities 0
0001437749-25-017252 7 33 CF 0 H Repayments Of Convertible Debt us-gaap/2025 Repayment of convertible note 1
0001437749-25-017252 7 34 CF 0 H Repayments Of Insurance Loans 0001437749-25-017252 Repayment of insurance loan 1
0001437749-25-017252 7 35 CF 0 H Payments Of Debt Issuance Costs us-gaap/2025 Expense for debt issuance costs due to fair value election on Anson Notes 1
0001437749-25-017252 7 36 CF 0 H Proceeds From Convertible Debt us-gaap/2025 Proceeds from Anson convertible notes, net of OID 0
0001437749-25-017252 7 37 CF 0 H Proceeds From Issuance Of Common Stock And Warrants Net 0001437749-25-017252 Proceeds from issuance of common stock and warrants, net of issuance costs 0
0001437749-25-017252 7 38 CF 0 H Proceeds From Issuance Of Private Placement us-gaap/2025 Proceeds from issuance of common stock and warrants issued in private placement, net of issuance costs 0
0001437749-25-017252 7 39 CF 0 H Net Cash Provided By Used In Financing Activities us-gaap/2025 Net cash provided by financing activities 0
0001437749-25-017252 7 40 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect us-gaap/2025 Net increase (decrease) in cash and cash equivalents 0
0001437749-25-017252 7 41 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations us-gaap/2025 Cash and cash equivalents at beginning of period 0
0001437749-25-017252 7 42 CF 0 H Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations us-gaap/2025 Cash and cash equivalents at end of period 0
0001437749-25-017252 7 44 CF 0 H Interest Paid Net us-gaap/2025 Cash paid for interest 0
0001437749-25-017252 7 45 CF 0 H Income Taxes Paid Net us-gaap/2025 Cash paid for taxes 0
0001437749-25-017252 7 47 CF 0 H Debt Conversion Converted Instrument Amount1 us-gaap/2025 Issuance of common stock as principal and interest conversion for convertible notes 0
0001437749-25-017252 7 48 CF 0 H Stock Issued As Offering Costs 0001437749-25-017252 Issuance of common stock warrants as offering costs 0
0001437749-25-017252 7 49 CF 0 H Conversion Of Stock Amount Converted1 us-gaap/2025 Conversion of Series A preferred stock into common stock 0
0001437749-25-017252 7 50 CF 0 H Warrants Issued1 0001437749-25-017252 Warrants issued pursuant to the Alvogen Agreement amendment 0
0001437749-25-017252 7 51 CF 0 H Amortization Of Prepaid Deferred Offering Costs 0001437749-25-017252 Amortization of deferred offering costs to additional paid-in-capital 0

Description
Field Name Field Description
adsh Accession Number. The 20-character string formed from the 18-digit number assigned by the SEC to each EDGAR submission.
report Represents the report grouping. This field corresponds to the statement (stmt) field, which indicates the type of statement. The numeric value refers to the “R file” as posted on the EDGAR Web site.
line Represents the tag’s presentation line order for a given report. Together with the statement and report field, presentation location, order and grouping can be derived.
stmt The financial statement location to which the value of the “report” field pertains.
inpth Value was presented “parenthetically” instead of in columns within the financial statements. For example: Receivables (net of allowance for bad debts of $200 in 2012) $700.
rfile The type of interactive data file rendered on the EDGAR web site, H = .htm file, X = .xml file.
tag The tag chosen by the filer for this line item.
version The taxonomy identifier if the tag is a standard tag, otherwise adsh.
plabel The text presented on the line item, also known as a “preferred” label.
negating Flag to indicate whether the plabel is negating.